Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC decreased its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 64.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 26,073 shares of the company’s stock after selling 46,536 shares during the period. Cubist Systematic Strategies LLC’s holdings in Centessa Pharmaceuticals were worth $235,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in CNTA. Quarry LP grew its holdings in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after buying an additional 3,108 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 69.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after buying an additional 4,423 shares during the period. EntryPoint Capital LLC purchased a new stake in Centessa Pharmaceuticals in the 1st quarter valued at about $109,000. Sandia Investment Management LP purchased a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at about $90,000. Finally, Fred Alger Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth about $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CNTA shares. Jefferies Financial Group boosted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Guggenheim boosted their target price on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. BMO Capital Markets boosted their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.17.

Centessa Pharmaceuticals Stock Up 4.2 %

NASDAQ CNTA opened at $16.66 on Tuesday. The stock has a market cap of $1.67 billion, a PE ratio of -11.73 and a beta of 1.46. Centessa Pharmaceuticals plc has a fifty-two week low of $5.58 and a fifty-two week high of $17.59. The business has a 50 day moving average price of $14.28 and a two-hundred day moving average price of $11.21. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gregory M. Weinhoff sold 25,000 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the transaction, the insider now directly owns 223,369 shares of the company’s stock, valued at approximately $3,350,535. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 288,492 shares of company stock valued at $4,641,902 in the last ninety days. Corporate insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.